Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TOP EMINENT HEALTHCARE

Top Eminent Healthcare Group Limited
（卓著健康集團有限公司）*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6877)

PROFIT WARNING ANNOUNCEMENT

This announcement is made by Top Eminent Healthcare Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 (the "**2025 Interim Period**"), the Group anticipates recording a net loss of approximately HK$1.7 million, as compared to a net profit of approximately HK$6.3 million for the corresponding period in 2024.

This anticipated loss is primarily attributable to: (a) one-off professional expenses of approximately HK$2.5 million incurred in relation to the change in the Company's controlling shareholder and the subsequent general offer triggered by such change during the first half of 2025. These expenses, which include legal, advisory, and other transaction-related professional fees, are non-recurring and not expected to impact the Group's future financial performance, having only temporarily affected the Group's results for the 2025 Interim Period; and (b) the Group's strategic shift toward the higher-margin B2C segment. While this transformation has already yielded positive results, including an expected improvement in gross profit margin, it has also involved transitional challenges. These are reflected in an expected decline in gross profit of approximately HK$2.1 million for the 2025 Interim Period as compared to the corresponding period last year, along with a moderate increase in advertising and promotion expenses of approximately HK$1.3 million, aimed at enhancing the Group's long-term brand visibility and customer engagement. The transition has already led to an expected improvement in the unaudited gross profit margin to 42% for the 2025 Interim Period, up from 39% in the corresponding period last year, demonstrating the effectiveness of the Group's strategic direction.

Excluding the aforementioned one-off professional expenses, the Group would have recorded a net profit of approximately HK$0.8 million for the 2025 Interim Period, reflecting the Group's underlying operational strength and adaptability amid strategic transformation.

As of the date of this announcement, the Group is still in the process of finalising its interim results for the 2025 Interim Period, which are expected to be published in August 2025. The information contained herein is based on a preliminary assessment of the information currently available to the Company's management and has not been confirmed, reviewed, or audited by the Company's auditor or audit committee. It may be subject to further adjustments.

The Board remains confident in the Group's long-term strategy and growth prospects, and expects the benefits of the strategic transformation to become more apparent in the second half of 2025, supported by enhanced brand visibility and customer engagement. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Top Eminent Healthcare Group Limited
Ji Guangfei
Chairman

Hong Kong, 18 July 2025

As at the date of this announcement, the Board comprises three Executive Directors, namely Mr. Ji Guangfei (Chairman and Chief Executive Officer), Ms. Li Jiang (Deputy Chairman) and Mr. Zhang Huanping; three Non-executive Directors, namely Mr. Li Jiong, Mr. Yuan Feng and Mr. Chung Cheuk Fan Marco; and three Independent Non-executive Directors, namely Mr. Zhou Zuyu (Lead INED), Ms. Hu Zhaoxia and Mr. Lyu Aiping.

* *For identification purpose only*